hero_left_circles
Abstracts
 

Abstract Information

hero_right_circles

Policy for Abstracts

ASTCT and CIBMTR thank everyone who submitted an abstract. Please view important deadlines and information about the late-breaking abstracts below.

Abstract Deadlines

  • Abstract Submission Opens: Monday, August 19, 2024
  • Abstract Submission Deadline: Wednesday, October 9, 2024 at 11:59 p.m. CT.
    • There will be NO extensions granted.
  • Abstract Accept/Reject Notification: Early December 2024
  • Late-Breaking Abstract Submissions: December 5-16, 2024
  • Oral Abstract Withdrawal DeadlineMonday, December 9, 2024 at 11:59 p.m. CT.
    • All withdrawal requests must be submitted in writing to tandemabstracts@astct.org.
    • Accepted abstracts that remain in the submission system on December 10, 2024, 12:00 a.m. CT, will be published online and in ASTCT's journal, Transplantation and Cellular Therapy
  • Complete Speaker Center Forms & ADA Support Request Deadline: Tuesday, December 10, 2024
  • Presenting Author Registration and Housing Deadline: Wednesday, January 8, 2025
  • Poster Abstract Withdrawal DeadlineFriday, January 10, 2025 at 11:59 p.m. CT.
    • All withdrawal requests must be submitted in writing to tandemabstracts@astct.org.
    • Accepted abstracts that remain in the submission system on January 11, 2025, 12:00 a.m. CT, will be published online and in ASTCT's journal, Transplantation and Cellular Therapy
  • Abstract Embargo Lifts: Friday, January 17, 2025
  • Draft Oral Abstract PowerPoint Due: Wednesday, January 22, 2025
  • Final Oral Abstract PowerPoint Due: Friday, January 31, 2025
  • Late-Breaking Abstract Embargo Lifts: Thursday, February 13, 2025

Abstract Eligibility

Work submitted for presentation should not have been reported previously in an archival scientific publication, either as an article or as an abstract, at the time of submission. Data that has been, or will be, presented at any other meeting before being presented at the 2025 Tandem Meetings of ASTCT and CIBMTR, will not be accepted for presentation.

Due to the overlap in the abstract submission and notification timelines for the 2024 ASH Annual Meeting, data submitted to the 2024 ASH Annual Meeting is acceptable for submission to the 2025 Tandem Meetings of ASTCT and CIBMTR. However, abstracts that are accepted and presented at other meetings, including ASH 2024, will not be considered for Tandem Best Abstract Awards. All submitted abstracts will be reviewed by the Tandem Meetings Scientific Organizing Committee, which has discretion to decide if an abstract presented at the 2024 ASH Meeting will be eligible for presentation at the 2025 Tandem Meetings.

If you submitted an abstract to ASH's annual meeting, please review ASH's copyright policies to ensure that you are in compliance: https://www.hematology.org/meetings/annual-meeting/abstracts/copyright-and-reuse-policy.

Conference Registration Fee

Abstract presenting authors will be eligible for the early registration rate even after standard and on-site registration rates apply.

Abstract Submission Fee

There is a $50 non-refundable abstract submission fee. Abstract submissions that have not paid the fee by Monday, October 9, 2024, will be removed from consideration.

Abstract Categories

  • Acute and Chronic Leukemia (AML, MDS, MPD ALL, CML) — Basic/Preclinical
  • Acute and Chronic Leukemia (AML, MDS, MPD ALL, CML) — Clinical
  • Acute Regimen-Related Toxicity and Supportive Care
  • Autoimmune Disorders — Transplant and Effector Cells
  • Cellular and Gene Therapy — Regulatory and Processing
  • Conditioning Regimens
  • Donor Safety, Unique Mobilizations and Health Services
  • Engineered Immune Cells (CAR-T, NK, TCR): Basic/Preclinical — Antigen Finding, Safety
  • Engineered Immune Cells (CAR-T, NK, TCR): Clinical — Immune Effector Cells for Heme Malignancies
  • Engineered Immune Cells (CAR-T, NK, TCR): Clinical — Immune Effector Cells for Solid Tumors
  • Gene Therapy and Editing
  • Graft Sources (related, matched and mismatched unrelated, haploidentical, autologous, cord blood, bone marrow and peripheral blood)
  • Graft-versus-Host and Graft-versus-Tumor — Basic/Preclinical
  • Graft-versus-Host and Graft-versus-Tumor — Clinical: Prevention, Treatment and Biomarkers
  • Hematopoietic Stem Cell Niche, Biology, Expansion and Marrow Failure Syndromes
  • Hemoglobinopathies, Primary Immune Deficiencies and Disregulation and Inborn Errors of Immunity
  • HSCT, Gene and Other Cellular Therapies in Countries With Constrained Resources
  • Immune Reconstitution and Immunobiology
  • Immunogenetics
  • Intersectionality, Diversity and Inclusion and Removing Barriers to Access
  • Late Effects, Quality of Life and Accelerated Aging
  • Lymphoma/CLL — Basic/Preclinical
  • Lymphoma/CLL — Clinical
  • Myeloma — Basic/Preclinical
  • Myeloma — Clinical
  • Relapse — Basic/Preclinical
  • Relapse — Clinical: Prevention and Treatment
  • Study Design and Statistics
  • Transplant and Cell Therapy for Aged and Geriatric Populations
  • Advanced Practice Professionals (for Advanced Practice Provider Track)
  • IT and Informatics for Transplant and Cellular Therapy (CIBMTR)
  • Infectious Diseases and Cytotoxic T Lymphocytes (for Infectious Disease Track)
  • Quality and Transplant Program Administration (for Administrative Director Track)
  • Transplantation Data Management (for Clinical Research Professionals/Data Managers Track)
  • Transplantation Pharmacology (for Pharmacists Track)

Nursing Track Abstract Categories

  • Administration
  • Clinical
  • Education
  • Research

Responsibility of Abstract Authors

The first author listed for each abstract serves as the presenting author and is the primary contact for all correspondence regarding the abstract. If there is a change to the presenting author, please contact tandemabstracts@astct.org.

The presenting author is responsible for the following:

  • Ensuring that all authors have read the abstract and agreed to be co-authors.
  • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by the Tandem Meetings of ASTCT and CIBMTR.
  • Obtaining all conflict-of-interest disclosure information from co-authors.
  • Making certain that abstracts are complete (tables included and labeled) and written in clear, concise and grammatically correct English, so that reviewers can focus solely on the scientific merits of the submission. For authors with any questions regarding the clarity, grammar, or spelling of their abstract, we encourage identifying and using an independent reviewer to edit the abstract prior to submission.
  • Ensuring that they will be prepared to present and to respond to questions regarding the abstract. If that is not the case, the authors should choose a poster as their preference.

Each abstract author agrees and certifies that they:

  • Have read the rules and agrees to be bound by them.
  • Are responsible for submission of the abstract in accordance with the rules and waives any and all claims against ASTCT/CIBMTR/Tandem Meetings of ASTCT and CIBMTR and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.

Abstract Review

Abstracts are peer reviewed on their scientific merits and according to subject category. Individuals submitting abstracts must indicate the appropriate review category. Abstracts may be re-categorized to a more appropriate category based on guidance from the Tandem Meetings Co-Chairs. The ASTCT, CIBMTR and Tandem Meetings of ASTCT and CIBMTR reserve the right to make minor editorial grammatical/spelling changes if required for clarity of presentation.

Abstract Corrections

All changes/edits to submitted abstracts are strictly the responsibility of the first author and must be conducted within the confines of the abstract submission portal. Requests for assistance in accessing abstracts to allow for modifications, should be submitted in writing to tandemabstracts@astct.org. The deadline for all correction requests is Monday, December 2, 2024. The Tandem Abstracts Team is unable to fulfill any correction requests after this deadline.

Abstract Withdrawals

Abstract withdrawals can be made within the submission system by the first author by Wednesday, October 9, 2024, at 11:59 p.m. PT.

After October 9, all withdrawal requests must be submitted in writing via email to tandemabstracts@astct.org by Monday, November 11, 11:59 p.m. PT. ASTCT and CIBMTR Staff cannot fulfill any withdrawal requests by phone. Accepted abstracts that remain in the submission system on November 12, 2024, at 12:00 a.m. PT, may be published online and in ASTCT's journal, Transplantation and Cellular Therapy, as submitted.

Incomplete Abstracts

Any submitted abstract deemed incomplete within the submission system on October 10, 2024, at 12:00 a.m. PT will be eliminated without further notification prior to abstracts being distributed to 2025 Tandem Meetings abstract reviewers.

Late-Breaking Abstracts

The submission of late-breaking abstracts will be allowed from December 5 – 16, 2024 at 11:59 p.m. PT.

Late-breaking abstract authors must complete a request for information to explain the need for submission during the late-breaking abstract submission process, which will be shared with the abstract reviewers and program Co-Chairs.

Embargo

Abstracts submitted for presentation will be embargoed by the author(s) and the 2025 Tandem Meetings, upon submission.

Abstracts submitted for presentation to the 2025 Tandem Meetings will be embargoed by the author(s) and the 2025 Tandem Meetings, upon submission. The embargo will be lifted, and abstracts will be made available for viewing on January 17, 2025.

Late-breaking abstracts will be subject to a separate embargo timeline and will be available for viewing on February 13, 2025.

Copyright

Authors assign copyright of the abstract to ASTCT upon submission, unless one of the authors is a U.S. Federal employee. This means that the identical abstract may not be republished or submitted to another meeting; however, Elsevier may grant permission for reuse of abstract content on behalf of ASTCT. You can request to re-use an abstract by clicking here.

General Submission Instructions

  1. No names or titles should be included in the abstract text. Names will be automatically hidden during the abstract review process and will be automatically inserted and properly formatted upon publication.
  2. Oral and Poster presentations:
    1. There will be approximately 100 abstracts selected for oral presentations during the scientific sessions during the meeting. Additional abstracts will be presented during the track conference sessions.
    2. Most other abstracts will be assigned by topic to a poster presentation.
    3. All accepted abstracts will be published as a supplement to the February 2025 issue of ASTCT's journal Transplantation and Cellular Therapy and distributed digitally prior to the 2025 Tandem Meetings of ASTCT and CIBMTR.
    4. If your abstract is accepted for oral presentation, you will be required to submit your slides for review by your session moderators AND to upload the final version of your slides before the meeting. These deadlines will be communicated to you, if accepted.
  3. Required elements of this system are designated by a red (*). If you fail to enter the required data, you will be prompted to go back and correct the omission before your abstract can be submitted.
  4. Verify that your abstract is correct by clicking Preview Abstract.
  5. Only when you are sure that your abstract is complete and in final form, click Submit Abstract.
  6. Presenting authors will be automatically informed of the unique ID numbers and passwords assigned to their abstracts. Abstracts may be viewed and modified at any time between submission and the deadline, using the assigned ID# and password.
  7. Eligibility: If your abstract is accepted for either poster or oral presentations, you can expect the following:
    1. You will not be eligible for a stipend for presenting a poster or oral abstract.
    2. You will be eligible for a registration discount for the Tandem Meetings.
  8. Character Count: There is a limit of 2500 characters (approximately 300 words) for the body of the abstract. Note that this character count does not include spaces or the title but does include the space allocated to tables. Figures are not included in the character count.
  9. Multiple Abstracts: There are no restrictions on the number of abstracts you may submit, or the number abstracts that you may present.
  10. Attached Figure: You may include up to 3 figures or images with your abstract - all figures and images must have titles. Words in that image or figure are not deducted from the total character count. Figures or images must be combined into one digital file for upload.
  11. Notification: Decisions on abstract acceptance /rejection will be communicated by early December 2024. Notification will be sent by email to the presenting author listed on each abstract.
  12. Abstract Corrections: All changes/edits to submitted abstracts are strictly the responsibility of the first author and must be conducted within the confines of the abstract submission portal.
  13. Incomplete Abstracts: Any submitted abstract deemed incomplete within the submission system on October 10, 2024, 12:00 a.m. PT will be eliminated without further notification prior to abstracts being distributed to the 2025 Tandem Meetings of ASTCT and CIBMTR abstract review team.

Technical Support

For help in submitting an abstract online, email tandem@confex.com or click on the "Report a Technical Issue" link in the submission application.

Questions

For all other questions regarding abstracts, please contact tandemabstracts@astct.org.

PLEASE NOTE: This information is for the general call for abstracts. The call for late-breaking abstracts will open on December 5, 2024. Late-breaking abstract authors must complete a request for information to explain the need for submission during the late-breaking abstract submission process, which will be shared with the abstract reviewers and program co-chairs.